Apheresis machine for extracorporeal elimination of LDL cholesterol in patients with familial hypercholesterolemia, hyperlipoproteinemia (a), hyperfibrinogenemia, transplant vasculopathy. The Plasmat ...
“The Transfusion Medicine Service in the Department of Pathology performs therapeutic apheresis on patients who have an illness associated with an abnormal cellular or plasma-based blood component,” ...
The global therapeutic apheresis market is poised for steady growth, forecasted to reach USD 4,285.0 million by 2035, up from USD 2,922.7 million in 2025, registering a CAGR of 3.9% over the forecast ...
Autologous peripheral SCT has largely replaced BMT for the treatment of cancer in both adults and children. Cells are collected by apheresis. The technique has been widely used in France since its ...
The fifth annual Apheresis Awareness Day is recognized on Tuesday, September 17, 2024, as designated by the American Society for Apheresis (ASFA). The purpose is to raise awareness of apheresis ...
On June 29, the U.S. Food and Drug Administration announced the approval of cold-stored apheresis platelets for the resuscitation of bleeding patients. Apheresis platelets are removed from a donor's ...
Lipoprotein apheresis involves the extracorporeal removal of LDL and lipoprotein(a) particles from whole blood or plasma by adsorption, precipitation or differential filtration. Used repetitively, ...
Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback